Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | APAF1 | O14727 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 3/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL475349 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL289043 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL7327 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL475350 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL4732053 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL23141133 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL1120026 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL4732052 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL19161120 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL30343446 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637185-B1 | Controlled-release formulations containing tryptophan and/or 5-hydroxytryptophan | AMBROS PHARMA S R L (IT) | 2008-08-20 | — | — | EP | claimed |
| CN-107304191-B | Indolylamine 2,3-dioxygenase inhibitor and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-111491923-B | N- (2-cyclohexylethyl) carboxamide derivatives, preparation and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-112384502-B | Cycloalkyl-substituted amide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-106883193-B | Indoleamine 2,3-dioxygenase inhibitor as well as preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-112384502-A | Cycloalkyl-substituted amide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110105275-B | Amide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111491923-A | N- (2-cyclohexylethyl) formamide derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190040025-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20170281595-A1 | FORMULATION AND METHOD TO INDUCE A DEEP STATE OF RELAXATION | KELLER RAYMOND MICHAEL (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2012113834-A1 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS OF INFLAMMATORY BRAIN INJURY IN PRETERM BORN INFANTS | BIOCRATES LIFE SCIENCES AG (AT) | 2012-08-30 | — | — | WO | disclosed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | disclosed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | disclosed |
| US-4778808-A | CONCENTRATING CULTURE BROTH WHILE CONTROLLING PH AND TEMPERATURE STABILITY | AJINOMOTO CO., INC. (JP) | 1988-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040025-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | IDO1, IDO2, INMT | KMT2A 1148/4885KDM4E 642/4885MAPT 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.